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1. Introduction 
Development of B-lymphoid cells is a highly ordered multi-step process that, in adult 
mammals, starts in bone marrow in a pool of self-renewing multipotential hematopoietic 
stem cells, which gradually commit to the lymphoid lineage and advance through high 
regulated differentiation pathways until formation of mature functional cells. Over the 
last few years, exceptional advances have been recorded in identifying primitive 
progenitors that lay the foundations of the lymphoid program while losing myeloid 
potential, along with patterns of transcriptional activity controlling lineage fate decisions 
and environmental cues that influence the differentiation pathway during normal 
hematopoiesis. Multicolor flow cytometry, controlled cell cultures, genetic marking 
systems, microarray technologies and xenotransplantation approaches are being 
extensively used to address fundamental questions on this regard. Of special interest is 
the stem cell research with relevance to hierarchy and early events in malignant 
lymphopoiesis, and to new insights into perspectives that may allow progress in means 
to protect and sustain the immune system during chemotherapy, inflammation, 
infection, and following hematopoietic transplantation. In this book chapter, we focus on 
the hierarchical structure of the early lymphoid system, the current knowledge about 
intrinsic and microenvironmental factors regulating the differentiation of lymphoid 
progenitors, and the emerging research to understand malignant lymphoid 
development. 
2. The early steps in the lymphoid development 
Mature blood cells are constantly replaced from a unique cell population of hematopoietic 
stem cells (HSC) residing in specialized niches within the bone marrow (BM), where the 
hematopoietic system is organized as a hierarchy of cell types that gradually lose multiple 
alternate potentials while commit to lineage fates and gain specialized functions (Baba et 
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al., 2004; Seita & Weissman, 2010). HSC possess two major characteristics: they are 
capable of maintaining their constant number by self-renewal and they are in charge of 
producing all mature blood cells through differentiation processes (Figure 1). 
Furthermore, HSC are mitotically inactive (quiescent) and divide very slow and 
intermittently under normal conditions, but are capable of proliferation and 
differentiation during recovery from chemotherapy or stress circumstances (Takizawa et 
al, 2011; Mayani, 2010; Passegue et al., 2005; Pelayo et al., 2006b). Movement into and out 
of a resting state might be crucial for ensuring that the correct number of new 
hematopoietic cells is produced.  
The lymphoid pathway proceeds through critical stages of differentiation of HSC to 
multipotential early progenitors (MPP), which upon progressive loss of self-renewal 
capacity, give rise to oligopotent progenitors. Downstream, the production of lineage-
committed precursors is crucial for cell maturation. Current knowledge about development 
of the lymphoid system is based, in great part, on the work done in animal models, 
demonstrating that lymphoid specification begins in the fraction of lymphoid-primed 
multipotent progenitors (LMPP). A series of studies using the transgenic RAG-GFP mouse 
(Igarashi et al., 2002) permitted us to determine that RAG+ early lymphoid progenitors 
(ELP) are capable of differentiating into T, B, NK and conventional dendritic cells (cDC) 
(Pelayo et al., 2005a; Pelayo et al., 2006a; Welner et al., 2008a). Studies using defined co-
cultures and short-term reconstitution assays have shown that ELP are also good producers 
of plasmacytoid dendritic cells (pDC) and of interferon-producing killer dendritic cells 
(IKDC), both being key components of the innate immune response to infections (Pelayo et 
al., 2005b; Welner et al., 2007). At the same time, ELP give rise to committed oligopotent 
common lymphoid progenitors (CLP), which are responsible for B- and NK- precursor cells 
production. CLP and lineage precursors have substantially lost the possibility of 
differentiating into the rest of the lineages.  
Due to ethical reasons and technical limitations, human hematopoietic stem cell research has 
been slower than it has been in mouse models. In humans, the early hematopoietic 
progenitors are confined in bone marrow to a cellular compartment that expresses CD34 
(Blom & Spits, 2006). The fraction of multipotent stem cells is characterized by the 
phenotype Lin-CD34+CD38-/loCD10-CD45RA-, whereas that of probably the earliest 
lymphoid progenitors is Lin-CD34+CD38-/loCD45RA+CD10+ and has been recently 
designated as multi-lymphoid progenitor (MLP) (Doulatov et al., 2010). According to 
Doulatov’s studies, MLP may be directly derived from HSC. However, a precise precursor-
product relationship needs to be determined (Figure 1). A description that fully matches the 
definition of mouse ELP is still missing, but cells with Lin-
CD34+CD38+CD45RA+CD7+CD10+ phenotype seem to represent good candidates (Blom & 
Spits, 2006; and our unpublished observations). Lin-CD34+CD38+CD45RA+CD10+ B/NK 
cells, which differentiate principally into B & NK cells, are considered the counterparts of 
CLP in mice (Figures 1 & 2) (Doulatov et al., 2010). Of special importance is the fact that 
increasing levels of CD10 correspond to B-lineage specification (Ichii et al., 2010). 
Downstream, the differentiation of fully committed precursors gives rise to B cells that 
eventually are exported to peripheral lymphoid tissues (see B cell development sections 
below).   
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Fig. 1. Early lymphoid development in humans. Within bone marrow (BM), self-renewing 
hematopoietic stem cells (HSC) give rise to multipotent progenitors (MPP), which have the 
ability to differentiate into common myeloid progenitors (CMP) and into multi-lymphoid 
progenitors (MLP). MLP might alternately derive from HSC. NK and B-lymphoid cells are 
produced from B/NK-derived lineage committed precursors. Mature hematopoietic cells 
are exported to peripheral blood (PB). Early progenitor cells may colonize the thymus via 
circulation, and initiate the T-lymphoid development pathway. NKP, natural killer cell 
precursor; BP, B cell precursor; TP, T cell precursor. 
The rigorous purification of human HSC and progenitor cell populations based on their 
surface phenotype has promoted the study of their biology in adult bone marrow, cord 
blood and G-CSF-mobilized peripheral blood (Figure 2). Importantly, some of their 
properties, including cell frequencies, developmental capacities, cell cycle status, 
transcription factors networks and growth factors production, show substantial differences 
between newborns and adults (Mayani, 2010). According to literature, we have found that 
most hematopoietic progenitors are more abundant in cord blood than in the adult tissues 
bone marrow and mobilized peripheral blood (Mayani, 2010). The implications of these 
discrepancies during haematological neoplastic diseases are not as yet clear. 
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Fig. 2. Prospective identification of human myeloid and lymphoid progenitor cells by flow 
cytometry. HSC and early progenitor cells reside in the Lin- CD34+ fraction of adult normal 
bone marrow (NBM), as well as in umbilical cord blood (UCB) and mobilized peripheral 
blood (MPB). Based on the surface expression of CD38, CD123 and CD45RA, multilymphoid 
progenitor cells (MLP) and most of the myeloid progenitors can be recognized (A). Further 
fractionation of Lin-CD34+CD45RA+ cells into CD7 & CD10-expressing cells allows the 
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identification of T-cell progenitors (TP), B/NK progenitors and ELP-like cells (C). Cell 
frequencies for each population from the different sources are shown (B and D panels). 
CMP, common myeloid progenitor; GMP, granulocyte & monocyte progenitor; MEP, 
megakaryocyte & erythrocyte progenitor. The identity and functions of Lin-CD34+CD38-
CD45RA+CD123hi cells still need more investigation. 
During biological contingencies -chemotherapy, infections and transplantation procedures-, 
the replenishment of the innate immune system from hematopoietic stem/progenitor cells 
appears to be critical. Interestingly, these seminal cells can proliferate in response to stress 
conditions and systemic infection by using mechanisms that apparently involve interferons 
and tumor necrosis factors, among others (Baldridge et al., 2011). Moreover, they are 
capable of self/non-self discrimination through Toll-like receptors (TLR), which recognize 
microbial components. Mouse stem cells and early B-cell progenitors express and use TLR, a 
mechanism that facilitates their differentiation to the innate immune system (Nagai et al, 
2006; Welner et al., 2008b; Welner et al., 2009). Recent work suggests that, as in mice, human 
primitive cells, including MLP, also express functional TLR (Kim et al., 2005; Sioud & 
Fløisand, 2007; De Luca et al, 2009; Doulatov et al, 2010). In shape with those findings, we 
have found that BM lymphoid progenitor-enriched fractions display TLR9 (Figure 3) and 
their differentiation potentials bias toward NK and DC production upon TLR9 ligation (RP 
& EV, unpublished observations). Thus, plasticity in primitive cells is vulnerable to extrinsic 
agents that can modify early cell fate decisions during infections or stress, suggesting that 
the stages of lineage restrictions are less abrupt than previously assumed (Welner et al., 
2008a).    
 
Fig. 3. Lymphoid progenitors from human bone marrow express TLR9. Adult bone marrow 
is fractionated according to cell surface expression of lineage markers, CD34, CD45RA and 
CD7/CD10 (A). Lin-CD34+CD45RA- HSC/MPP, Lin-CD34+CD45RA+CD7/CD10- myeloid 
progenitors (MP) and Lin-CD34+CD45RA+CD7/CD10+ lymphoid progenitors (LP) were 
tested for their intracellular expression of TLR9 by flow cytometry using a specific anti-TLR9 
antibody (B).  
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3. The B cell antigen receptor (BCR) and bone marrow B cell development 
The main function of mature immunocompetent B cells is to make antibodies upon 
recognition of particular new or recurrent antigens by the B cell receptor (BCR). The BCR is 
a membrane-bound complex of proteins, consisting of a heterodimer of identical pairs of 
immunoglobulin (Ig) heavy and light chains, which are responsible for the clonal diversity 
of the B cell repertoire and the antigen identification, but are unable to generate signals and 
trigger biological responses after antigen binding. This function is mediated by the 
disulfide-coupled heterodimer of Ig (CD79a) and Ig (CD79b), which is non-covalently 
associated with the Ig antigen recognition unit (Figure 4A). Ig/Ig signaling is dependent 
on distinct tyrosine-based activation motifs localized in the cytoplasmic tails of these 
proteins. It is the sequential expression and assembly of the BCR components that defines 
each developmental stage of the B cell pathway, and, therefore, each stage is characterized 
by a particular form of BCR, reflecting the progression of receptor assembly (Fuentes-
Pananá et al., 2004a). 
To achieve BCR clonal diversity, the Ig heavy and light chain genes are composed of 
constant and variable regions. The variable region is formed by a series of segments V 
(variable), D (diversity) and J (joining) (Figure 4B), which are brought together by a highly 
ordered process of VDJ recombination accomplished by the products of the recombinase-
associated genes 1 and 2 (RAG1 and RAG2) occurring first in the heavy and then in the light 
chain loci (Thomas et al., 2009). ProB and PreB stages are characterized by rearrangements 
of the Ig heavy and light chains, respectively (Figure 5) (Fuentes-Pananá et al., 2004b), and 
further divided according to the status of the recombination. In mice, ProB-A is the sub-
stage during which the heavy chain is in germ line state, whereas during ProB-B the heavy 
chain D and J fragments are recombined, and in ProB-C, V-DJ is recombined. In large PreB 
cells, the preBCR is already expressed in surface and the light chain V and J fragments are in 
germ line state, while in small PreB cells light chain V-J is recombined (Hardy et al., 1991). 
These stages are better known in humans as Early ProB or Pre-proB (A), ProB (B), PreB I (C), 
large and small PreB II (Figure 5). In the ProB stage Ig and Ig are expressed at cell surface 
in association with chaperon proteins such as calnexin (the proBCR). As soon as the heavy 
chain is successfully recombined, it is assembled with Ig and Ig and the surrogate light 
chains 5 and VpreB to form the preBCR. Surface expression of this receptor marks the 
transition to the preB stage (Figure 5) (Fuentes-Pananá et al., 2004a; 2004b).  
In addition to their VDJ recombination status and pattern of surface marker expression, 
ProB and PreB stages can be recognized by their proliferative state (Hardy et al., 1991). 
RAG-1 and RAG-2 enzymes are tightly regulated during the cell cycle, being highly active in 
G0 and degraded before the cell enters S phase (Li et al., 1996). By assuring that proliferation 
and recombination are mutually exclusive mechanisms, the developing B cell guarantees 
that no events of non-homologous recombination will occur during DNA replication, thus 
avoiding an increase in the mutation rate. 
3.1 Self-recognition and peripheral B cell development 
Once the mature BCR is present in the surface of immature B cells, it is finally able to 
interact with conventional polymorphic ligands, and selection at this stage is designed to 
test the receptor-ligand interaction. Intimate contact between the immature B cell and the 
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stromal cells of the bone marrow allows those receptors capable of recognizing self-antigens 
to be identified and eliminated through a variety of mechanisms collectively termed 
"tolerance". Non-self-reactive B cells exit to the periphery and reach the spleen where they 
are again tested for reactivity against self-antigens before they transition to the mature stage 
(Figure 5) (von Boehmer & Melchers, 2010). Three main mechanisms of B-cell tolerance are 
known: receptor editing, deletion of auto-reactive clones (negative selection) and anergy. 
Only those B cells that carry receptors without self-specificity are allowed to exit the bone 
marrow and become mature B cells in peripheral lymphoid organs.   
 
Fig. 4. The B cell antigen receptor (BCR). A) Heavy and light chains are comprised of 
variable regions where VDJ recombination occurs (shown in dark blue) and constant regions 
(green). The signaling domains are present in the cytoplasmic leaflet of Ig and Ig. B) 
Variable regions are formed by a number of segments termed V (variable), D (diversity) and 
J (joining) within the heavy chain, and by segments V and J within the light chain, which are 
brought together by a VDJ recombination process. Randomly, D and J segments recombine 
at first, followed by V segments joining the DJ fragment (shown in dark blue squares is an 
example of segment choice). This mechanism is responsible for the extensive repertoire of 
BCR specificities. 
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Fig. 5. Normal and leukemic B cell development. B cell stages can be divided according to 
the main processes guiding development: receptor assembly, self-recognition and 
activation (top panel). Receptor assembly occurs in bone marrow (light blue box) by VDJ 
recombination in the Pro-B and Pre-B stages, whereas self-recognition starts in bone 
marrow and ends in periphery, and activation takes place at peripheral level. 
Nomenclature for each sub-stage in mice is shown in black letters while the most common 
nomenclature for their counterparts in humans is shown in red letters. The dashed lines 
separating all stages indicate checkpoints at which signaling from the preBCR and BCR is 
required for positive selection and progression along the B-cell maturation pathway. The 
proBCR, preBCR, and mature receptor are also illustrated in their respective stages. 
Replication and recombination processes are mutually exclusive as denoted by the 
circular arrows and VDJ signs inside the cell. The replication stages are also frequently 
compromised in pediatric B cell acute leukemia. Black lines under IL-7R and preBCR 
indicate the stages where these receptors are most required. The differential thickness in 
the IL-7R line shows the sub-stages where a higher (nanograms) or lower (picograms) 
concentration of the IL-7 is required. Homeostatic and leukemic expression of 
transcription factors along the B cell pathway are shown in the middle and bottom panels. 
Blue bars mark normal gene expression, and the most common modified forms of the 
transcription factors associated with B cell acute lymphoblastic leukemia are revealed. 
HSC, hematopoietic stem cell. 
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On the basis of their cell-surface phenotype, peripheral immature B cells are further divided 
into transitional 1 (T1, AA4+IgMhighCD23-) and transitional 2 (T2, AA4+IgMhighCD23+). T1 
cells inhabit the spleen's red pulp and give rise to T2 cells (Allman et al., 2001). There is an 
additional population designated T3, but it is controversial whether this is a population in 
line in the progression to the mature stage or whether it represents a population of anergic 
cells (Merrell et al., 2006). 
3.2 Innate and adaptive mature B cell populations 
Following antigen binding, mature B cells activate pathways that lead to proliferation and 
further differentiation into antibody-producing B cells (plasma cells) or memory B cells. In 
the spleen, mature B cells are sub-divided into follicular (FO, AA4.1-CD21intCD23high) and 
marginal zone (MZ, AA4.1-CD21highCD23-) B cells according to both their location and their 
cell-surface phenotype. A distinct subset of mature B cells is preferentially present in the 
peritoneal cavity; these are known as B1 cells [B220+CD11b+CD5+ (B1a) or CD5- (B1b)]. 
Among them, FO B cells are responsible for adaptive antibody responses, whereas MZ and 
B1 mature populations respond rapidly to antigenic stimulus but do not go through 
germinal-center reactions and thus their response can be independent of T cell help (Martin 
et al., 2001). Therefore, MZ and B1 B cells are thought to be part of an innate–like response. 
The origin of both of these populations is not well understood. While MZ B cells share part 
of FO pathway, the fetal liver was thought to originate a large fraction of the adult B1 B cells 
(Tung et al., 2006). Recently, a novel developmental model suggests that some B1 cell 
progenitors can be produced in bone marrow (Esplin et al., 2009). 
3.3 Regulation of B lineage commitment: The critical role of preBCR tonic signaling, 
IL-7R and transcription factors in context 
Limitation of lineage choice during development is regulated by a combination of signaling 
pathways and transcription factors (TF). In mice, the main receptor controlling the ProB 
stage is the IL-7R, which is composed of a  chain (IL-7R) and the common cytokine 
receptor  chain (c). Deletion of IL-7R or c leads to developmental arrest at the early ProB 
stage (von Freeden-Jeffrey et al., 1995; Cao et al., 1995).  
IL-7 activates the major signaling pathway JAK–STAT, with STAT5 being the essential 
mediator of IL-7 signals in early B cell development (Yao et al., 2006).  
By the other hand, an important characteristic of the developmental process that 
distinguishes B and T lymphocytes from other cell lineages is the continuous selection of 
these lymphoid cells for their ability to express a competent, non-self receptor. B cells that 
fail to express a receptor are eliminated. Thus, BCR and BCR-like receptors must generate 
active permissive signals that allow differentiation through the different developmental 
stages. Because the preBCR lacks of the light chain and therefore of the capacity to bind 
polymorphic ligands, it has been proposed that this receptor is able to signal 
constitutively and independently on ligand, an activity also known as tonic signaling. 
Although there is little understanding of how tonic signals are generated, the view is 
supported by receptor-less B cells able to differentiate into mature B cells by expression of 
a chimeric construct of Ig and Ig positioned in the cell surface membrane (Bannish et 
al., 2001).   
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Once the preBCR is expressed at the end of the proB stage, it can take over many of the 
functions performed by the IL-7 receptor signaling. Both receptors act individually and 
together to allow B cell development (Figure 5). Like IL-7R, the preBCR promotes 
mechanisms of positive selection, survival and proliferation (Ramadani et al., 2010; Yasuda 
et al., 2008). The CCND3 gene, which encodes for cyclin D3, is essential for PreB cell 
expansion and integrates IL-7R and preBCR signals (Cooper et al., 2006). 
Downstream the IL-7 and preBCR receptors, a handful of transcription factors (TF) are critical 
for commitment to the B cell lineage and early development; these include E2A/TCF3 
(immunoglobulin enhancer binding factors E12/E47/transcription factor 3), EBF1 (Early B cell 
Factor 1) and PAX5 (Paired box 5) (Figure 5). Loss of E2A and EBF1 blocks entry into the B cell 
lineage, while loss of PAX5 redirects B cells into other lineages (Nutt et al., 1999; O’Riordan & 
Grosschedl, 1999). Acting together with E2A, EBF1 and STAT5, one of the main molecular 
functions of PAX5 is to allow VDJ recombination (Hsu et al., 2004). Also, E2A, PAX5, IKZF1 
and RUNX1, among other TF, are responsible for RAG expression (Kuo & Schlissel, 2009). 
Moreover, IL-7R signaling fulfills an essential role in early B cell development, with STAT5 
participating in the activation of the B cell regulatory genes E2A, EBF1 and PAX5. E2A 
encodes two TF via alternative splicing, E12 and E47. In mice lacking the E2A gene, the B cell 
lineage is lost, there is no heavy chain recombination, and the expression of the B cell-restricted 
genes EBF1, PAX5, CD79A/B and VPREB1 (CD179A) is also affected.  
Enforced expression of EBF1 and PAX5 is sufficient to overcome the developmental block in 
mice deficient in E2A, IL-7 or IL-7R, further illustrating the transcriptional hierarchy of the 
B cell-specific program triggered by IL-7 receptor signaling (Nutt & Kee, 2007). EBF1 acting 
together with PAX5 drives the expression of many genes critical for early B cell 
development and B cell function, including FOXO1, MYCN, LEF1, BLNK, CD79A (MB-1), 
RAG2, CD19 and CR2 (CD21) (Nutt & Kee, 2007; Smith & Sigvardsson, 2004).  
Although PAX5 is a positive regulator of B-cell specific genes, also functions as a repressor 
of non B-lineage genes such as M-CSFR, NOTCH1 and FLT3 (Cobaleda et al., 2007) so B cell 
development is unidirectional and mostly irreversible in homeostatic conditions. 
Also important for lymphoid development are members of the Ikaros family of TFs, mainly 
IKZF1 (which encodes Ikaros) and IKZF3 (which encodes Aiolos). Ikaros activates B cell 
genes and represses genes that are unrelated to the B lineage. Expression of IKZF1 and 
IKZF3 is regulated by alternative splicing, which produces long isoforms (Ik-1, Ik-2, Ik-3, 
Aio-1, Aio-3, Aio-4 and Aio-6) that efficiently bind to DNA, and short isoforms (Ik-4, Ik-5/7, 
Ik-6, Ik8, Aio-2, Aio-5) that are unable to bind DNA with high affinity and do not activate 
transcription (Liippo et al., 2001). Ikaros is activated in early stages of lymphopoiesis and is 
required for both early and late events in lymphocyte differentiation. Aiolos is not required 
during the early specification of the B and T lineages but is essential during further B cell 
maturation. They also act in concert to promote preB cell cycle exit and transition to small 
PreB stage (Ma et al., 2010). 
3.4 Human B cell development 
Selection processes operating on developing B cells are similar in all mammals. Thus, early B 
cell development in humans is also mainly guided by VDJ recombination and by the 
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proliferative expansion of clones that have successfully completed the rearrangement of 
their receptors, whereas late development is led by mechanisms of tolerance to self-antigens. 
All these processes in humans are less well understood than are their counterparts in mice. 
Importantly, human B cells can still be generated in severe combined immunodeficiency 
(SCID) patients with mutations in the IL-7R gene, suggesting that IL-7 signaling is not 
essential for human B cell development (Puel et al., 1998) although a recent study has 
demonstrated that in vitro human B cell production is dependent on IL-7 (Parrish et al., 
2009). The fine regulatory mechanism separating proliferation and differentiation might 
explain why the proliferating ProB and PreB sub-stages are the ones generally found to be 
compromised in human pediatric B-cell acute lymphoblastic leukemia (B-cell ALL) and why 
this disease is characterized by leukemic blast cells that are often unable to progress through 
the differentiation pathway. This tendency to be arrested in proliferative states might result 
in an increased rate of mutations, leading to formation of neoplastic cells. Supporting the 
later, mice expressing B cell mutants in the adaptor protein BLNK are arrested in the large 
PreB stage and often develop B cell malignancies (Flemming et al., 2003). Proliferative stages 
occur in the early ProB, PreB-I and large PreB-II fractions (Figure 5). 
4. Acute lymphoblastic leukemia 
Acute lymphoblastic leukemia (ALL) is a disorder characterized by the monoclonal and/or 
oligoclonal proliferation of hematopoietic precursor cells of the lymphoid series within the 
bone marrow. At present, ALL is the most frequent malignancy in children worldwide and 
a serious problem of public health, constituting 25% of all childhood cancers and 75%-85% 
of the cases of childhood leukemias (Perez-Saldivar et al., 2011). Near to 80% of ALL cases 
have precursor B-cell immunophenotype, while approximately 15% show T-cell 
immunophenotype. Even when a relatively high efficiency of therapeutic agents has been 
demonstrated (Pieters & Carroll, 2010), there has been a slight but gradual increase in the 
incidence of ALL in the past 25 years, and appears to be highest in Hispanic population, 
which also show superior rates of high risk patients (Fajardo-Gutiérrez et al., 2007; 
Abdullaev et al., 2000; Perez-Saldivar et al., 2011; Mejía-Aranguré et al., 2011). Factors such 
as drug resistance, minimal residual disease, cell lineage switch, and the rise of mixed 
lineages often put the success of treatment at risk and change the prognosis of the illness. 
The molecular mechanism involved in these phenomena and the identities of the target 
hematopoietic populations have not been completely defined, due in part, to the fact that 
neither the precise origin of the disease, nor the susceptibility of primitive leukemic cells to 
extrinsic factors, is known. 
4.1 The origin of ALL 
Over the last two decades, cancer stem cells (CSC) have been defined as cells within a tumor 
that possess the capacity to self-renew and to cause heterogeneous lineages of cancer cells 
that comprise the tumor (Clarke et al., 2006). According to MF Greaves, who proposed the 
original hypothesis for leukemogenesis, multiple consecutive carcinogenic hits in 
hematopoietic cells may drive the malignant transformation (Greaves, 1993; Greaves & 
Wiernels, 2003), where the second oncogenic event on pre-leukemic clones could be 
indirectly promoted by delayed infections (Greaves, 2006; Mejía-Aranguré et al., 2011). Our 
general current view suggests the occurring of oncogenic lesions in early development or in 
www.intechopen.com
 Advances in Hematopoietic Stem Cell Research 
 
288 
a primitive cell that result in the abnormal differentiation of leukemic stem cells. Among the 
various factors that hit the HSC fraction, anomalous microenvironmental cues may 
contribute to trigger and support the leukemic behaviour of precursor cells (Figure 6). 
Although CSC in myeloid leukemias have been strictly depicted as the responsible cells for 
tumour maintenance, which clearly keep the biological hierarchy within the hematopoietic 
structure (Dick, 2008), identification of a rare primitive and malignant cell with intrinsic 
stem cell properties and the ability to recapitulate the acute lymphoblastic leukemia has 
been more complicated (Bomken et al.,2010), particularly due to the genetic diversity of the 
disease and the lack of appropriate in vitro and in vivo models. 
 
Fig. 6. Leukemic stem cell model. Normal hematopoietic stem cells (HSC) give rise to 
progenitors and mature blood cells within a hierarchical structure in the bone marrow. As a 
result of multiple and consecutive oncogenic hits on HSC including genetic and 
microenvironmental alterations, a malignant counterpart (the leukemic stem cell, LSC) 
emerge, which maintains some degree of developmental potential, generating the leukemic 
progenitor and blast cells. 
Cell culture systems revealing alterations in early hematopoiesis, the existence of leukemic 
clones with unrelated DJ rearrangements and cytogenetic abnormalities on cells lacking 
lineage markers, have strongly suggested the participation of primitive cells in ALL. 
Moreover, data showing cells with immature phenotypes capable of engrafting and 
reconstituting leukemia in immunodeficient mice, lead to believe that, as in AML & CML, 
the hierarchy structure of the hematopoietic system is kept in ALL, and infant B cell-
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leukemia initiating cells have undifferentiated characteristics (Espinoza-Hernandez et al., 
2001; Cobaleda et al., 2000; Cox et al., 2004; Cox et al., 2009). To characterize ALL progenitor 
cells, Blair and colleagues have purified by flow cytometry a number of cell fractions based 
on the expression of CD34 and the B-lymphoid marker CD19. Regardless the risk stratum of 
the patient, CD34+CD19- cells, but not committed B precursors, were able to reconstitute the 
disease in NOD/SCID models (Cox et al., 2004). Moreover, CD133+CD38-CD19- primitive 
cells residing in ALL BM are suggested to be the leukemia-initiating cells and responsible of 
drug-resistant residual disease (Cox et al., 2009). However, recent studies have remarkably 
shown that precursor blasts can also reestablish leukemic phenotypes in vivo, conferring 
them stem cell properties (Heidenreich & Vormoor, 2009; Bomken et al., 2010). Using novel 
intrafemoral xenotransplantation strategies, Vormoor’s Lab has found that all differentiation 
stages of B precursor cells within CD34+CD19+ and CD34-CD19+ fractions are able to 
successfully engraft and recapitulate the original patient’s disease in long-term systems, 
suggesting that committed cells in ALL do not lose the self-renewal stem cell property while 
they mature (le Viseur et al., 2008) (Figure 5), though their multi-lineage potential is 
uncertain.  
These discordant results unveil that key questions regarding leukemic stem cells and the 
earliest steps of the lymphoid program in ALL still to be solved. Recently, the combination 
of clonal studies and alterations on genetic copies along with xenotransplant models, 
showed unsuspected genetic diversity, supporting multiclonal evolution of leukemogenesis 
rather than lineal succession (Dick, 2008). Thus, a less rigid structure of CSC models should 
further take account of functional plasticity and clonal evolution to understand CSC biology 
and to develop novel, stem/progenitor cell-directed therapies (Bomken et al., 2010).  
4.2 Genes, cytogenetic alterations and transcription factors in B-cell leukemogenesis 
The leukemogenic program is characterized by arrest of differentiation pathways, increased 
cell proliferation, enhanced self-renewal, decreased apoptosis rates and telomere 
maintenance. It is thought that together these alterations result in production of highly 
proliferative clones of immature leukemic blast cells with intrinsic survival advantage and 
limitless replicative potential (Warner et al., 2004).  
Gain or loss of function of transcription factors such as E2A, EBF1, PAX5 and Ikaros affect 
homeostatic B cell lymphopoiesis in murine models, and are often associated with 
malignant transformation in humans, supporting conserved roles for these TFs and their 
activating signaling pathways (Figure 5) (Pérez-Vera et al., 2011). 
A high frequency of ALL patients has genetic lesions -mostly chromosomal translocations- 
associated with leukemic cells. E2A is often translocated with several partners, including 
PBX1 [t(1;19)(q23;p13)] and HLF [t(17;19)(q22;p13)], which are detected in 5-6% and 1% of 
ALL children, respectively. E2A-PBX1 is a potent transcriptional activator of the WNT16 
oncogene (McWhirter et al., 1999), while E2A-HLF functions as a survival factor of early B 
cells by activating expression of the anti-apoptotic genes SNAI2 (SLUG) and LMO2. 
Accordingly, gene silencing of LMO2 in an E2A-HLFpos cell line induced apoptotic cell death 
(Hirose et al., 2010). RUNX1 is also a frequent target for chromosomal rearrangements and 
mutations in ALL. 25% of children and 2% of adults of ALL patients carry the 
ETV6/RUNX1 fusion as a result of the translocation t(12;21)(p12;q21), which may play a role 
www.intechopen.com
 Advances in Hematopoietic Stem Cell Research 
 
290 
regulating the B lineage-specific transcriptional program at an early stage (Durst & Hiebert, 
2004). SNP array analysis of ETV6-RUNX1 samples has recently identified multiple 
additional genetic alterations, but the role of these lesions in leukemogenesis remains 
undetermined (van der Weyden et al., 2011). 
Genome-wide analysis has recorded abnormalities in PAX5 and EBF1 in up to 32% of 
children and 30% of adults with B ALL, and in 35% of relapsed cases (Mullighan et al., 
2007). Currently, five PAX5 fusions have been identified with the gene partners LOC392027 
(7p12.1), SLCO1B3 (12p12), ASXL1 (20q11.1), KIF3B (20q11.21) and C20orf112 (20q11.1), 
with the resulting chimeric proteins expressing lower levels of PAX5 and its target genes 
(An et al., 2008). EBF1 alterations are common in patients with poor outcomes and are 
particularly frequent (25%) in relapsed children (Harvey et al., 2010). 
The MLL (mixed lineage leukemia) gene is often rearranged in leukemias with myeloid and 
lymphoid phenotype, probably indicating a very early multipotent progenitor origin. More 
than 50 fusions involving MLL have been documented. Among them, the MLL-AF4 
[t(4;11)(q21;q23)] translocation is present in 80% of infant, 2% of children, and 5-10% of adult 
ALL (McCarthy, 2010).  
The BCR-ABL1 translocation [t(9;22)(q34;q11), also known as Philadelphia chromosome] is 
found in 5% of pediatric and 25% of adult B cell ALL. An important consequence for this 
translocation is the over-expression of STAT5. STAT5 inactivation results in cell cycle arrest 
and apoptosis of BCR-ABLpos malignant B cells and BCR–ABL1pos STAT5 knockout mice do 
not develop leukemia (Malin et al., 2010). Interestingly, genome-wide analysis of B cell ALL 
has identified mutations in the STAT5 upstream regulators JAK1 and JAK2 in up to 10% of 
patients, and patients BCR-ABLpos or with JAK1&2 mutations have a similar gene expression 
profile and prognosis (Malin et al., 2010). JAK2 mutations lead over-expression of CRLF2 (also 
known as thymic stromal lymphopoietin receptor) which forms a heterodimeric complex with 
the IL-7R (Harvey et al., 2010). In a subset of cases, CRLF2 promotes constitutive dimerization 
and cytokine-independent proliferation. Finally, high expression levels of the short Ikaros 
isoforms, particularly the dominant negative Ik-6, are also associated with high risk leukemia 
(Sun et al., 1999). Most of the BCR-ABLpos B ALL patients have deletions in IKZF1 and 
increased levels of the short isoforms; however, Ik-6 has also been found to be elevated in 
BCR-ABLneg patients (Mullighan et al., 2008). It has been proposed that the high level of Ikaros 
short isoform expression is due to genetic lesions. Supporting this idea, IKZF1 somatic 
deletions have been found in a number of recurrences and are strongly associated with 
minimal residual disease (Mullighan et al., 2009). A summary of homeostatic and leukemic 
expression of transcription factors along the B cell pathway is shown in Figure 5. 
Despite these important advances in the definition of genetic abnormalities that are 
prevalent in ALL, the disease is heterogeneous at the molecular level, and possibly it is the 
result of combination of genetic and epigenetic alterations. Furthermore, high frequencies of 
ALL cases seem not to be associated to intrinsic genetic abnormalities, opening the 
possibility of microenvironmental cues leading to disease. 
4.3 Leukemic microenvironmental cues? 
The complexity of leukemogenesis increases when we consider the indubitable influence of the 
bone marrow microenvironment in the hematopoietic development, which is a network of 
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cells (mesenchymal cells, osteoblasts, fibroblasts, adipocytes, endothelial cells, etc) and their 
products (extracellular matrix molecules, cytokines and chemokines) that support 
hematopoiesis. Under physiological conditions, the appropriate production of mature blood 
cells throughout life is sustained by special niches that provide stem and progenitor cells with 
regulatory signals essential for their maintenance, proliferation and differentiation (Nagasawa 
et al., 2011). Among secreted factors, CXCL12, FLT3-L, interleukin 7 and stem cell factor are 
critical for commitment to the lymphoid program and normal B cell development is supported 
by two stage specific cellular niches within central bone marrow: a CXCL12/SDF1 expressing 
niche, and a IL-7 expressing niche. B cell precursors are thought to move from one to another 
as differentiation progresses (Tokoyoda et al., 2004; Nagasawa, 2006). The role of the bone 
marrow microenvironment in carcinogenesis has been conceived through three possible 
mechanisms: competition of tumor cells for normal HSC niches, which may allow their 
maintenance and survival; manipulation of the environment to promote tumor progression 
and disruption of hematopoietic-niche communication that drives oncogenesis (Raaijmakers, 
2011). Although these potential mechanisms are tempting, their contribution to ALL remains 
formally unexplored. It has been proposed by Sipkins and colleagues that the leukemic cells 
derived-tumor microenvironment impairs the behavior of normal hematopoietic cells 
(Colmone et al., 2008). Furthermore, a number of alterations have been recorded in the marrow 
microenvironment of ALL, including chromosomal aberrations in mesenchymal stem cells, 
anomalous expression of adhesion molecules, abnormal levels of CXCR4 and growth factors, 
as well as prevalence of pro-inflammatory cytokines (Menendez et al., 2009; Geijtenbeek et al., 
1999; Juarez et al., 2009; and our unpublished results). Whether an abnormal 
microenvironment anticipates the leukemic stage or is a consequent fact, is still an open issue.   
5. Conclusion 
Much has been learned about identity, function and intercommunication of seminal cells 
within the hematopoietic system from animal models. However, our understanding of the 
hierarchy and regulation of human stem/progenitor cells is still incomplete and the 
hematopoietic charts have been in constant re-construction over the last few years. 
Furthermore, while it has long been recognized that intrinsic abnormalities in primitive 
hematopoietic cells may cause hematological disorders, it has also become clear that changes 
in both cell composition and function of the bone marrow microenvironment might govern 
stem cell activity and lead to disease. Future progress in these areas will be decisive to 
suggest novel classification, prognosis and treatment venues. 
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